3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Recruiting
1
Sponsor Class
OTHER
17
INDUSTRY
16
FED
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Lymphoid
1
Conditions
Lymphoma
1
Leukemia, Lymphocytic, Chronic, B-Cell
1
Leukemia
1
Interventions
Clofarabine
2
zanubrutinib
1
venetoclax
1
talabostat
1
ibrutinib
1
acalabrutinib
1
Topotecan
1
Tablets
1
Rituximab
1
PT-100 dipeptide
1
Mitoxantrone
1
Midazolam
1
Ketamine
1
Exercise
1
Etoposide
1
Dosage Forms
1
Azacitidine
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
FED
×
zanubrutinib
×
Other hematologic neoplasm
×
Clear all
NCT06520098
2025-10-14
Benefit VA
VA Office of Research and Development
Phase 2
Recruiting
100 enrolled